Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial

BACKGROUND: More effective vaccine candidates against variants of concern as a booster dose are needed in people primed with two-dose inactivated COVID-19 vaccines. METHODS: This randomised, double-blinded, investigator-initiated phase 2 trial aims to evaluate immunogenicity, durability, and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yuemiao, Ma, Xupu, Yan, Guanghong, Wu, Ying, Chen, Yanli, Zhou, Zumi, Wan, Na, Su, Wei, Liu, Feng-Wei, Dai, Mu-Xian, Yang, Mei, Li, Chunmei, Yu, Xuanjing, Zhang, Liang, Wang, Zhongfang, Zhou, Tai-Cheng, You, Dingyun, Wei, Jia, Zhang, Zijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517939/
https://www.ncbi.nlm.nih.gov/pubmed/36188435
http://dx.doi.org/10.1016/j.eclinm.2022.101680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517939/
https://www.ncbi.nlm.nih.gov/pubmed/36188435
http://dx.doi.org/10.1016/j.eclinm.2022.101680

Ejemplares similares